NO2721710T3 - - Google Patents

Info

Publication number: NO2721710T3
Authority: NO; Norway

Application number

NO12803361A

Other languages

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-08-21

Filing date

2012-06-19

Publication date

2018-03-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54148580&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2721710(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2012-06-19 Application filed filed Critical

2018-03-31 Publication of NO2721710T3 publication Critical patent/NO2721710T3/no

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04N—PICTORIAL COMMUNICATION, e.g. TELEVISION
- H04N7/00—Television systems
- H04N7/18—Closed-circuit television [CCTV] systems, i.e. systems in which the video signal is not broadcast
- H04N7/188—Capturing isolated or intermittent images triggered by the occurrence of a predetermined event, e.g. an object reaching a predetermined position

NO12803361A 2014-08-21 2012-06-19 NO2721710T3 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201462039969P	2014-08-21	2014-08-21

Publications (1)

Publication Number	Publication Date
NO2721710T3 true NO2721710T3 (es)	2018-03-31

Family

ID=54148580

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO12803361A NO2721710T3 (es)	2014-08-21	2012-06-19

Country Status (48)

Country	Link
US (5)	US9663526B2 (es)
EP (1)	EP3183247B9 (es)
JP (1)	JP6218260B2 (es)
KR (1)	KR101877189B1 (es)
CN (1)	CN107074867B (es)
AP (1)	AP2017009748A0 (es)
AR (1)	AR101599A1 (es)
AU (1)	AU2015304883B2 (es)
BR (1)	BR112017003054B1 (es)
CA (1)	CA2900855C (es)
CL (1)	CL2017000406A1 (es)
CO (1)	CO2017001603A2 (es)
CR (1)	CR20170066A (es)
CU (1)	CU24435B1 (es)
CY (1)	CY1119771T1 (es)
DK (1)	DK3183247T3 (es)
DO (1)	DOP2017000048A (es)
EA (1)	EA032609B1 (es)
EC (1)	ECSP17010156A (es)
ES (1)	ES2655971T3 (es)
GE (1)	GEP20197003B (es)
GT (1)	GT201700035A (es)
HR (1)	HRP20171913T1 (es)
HU (1)	HUE035553T2 (es)
IL (1)	IL250709B (es)
LT (1)	LT3183247T (es)
MA (1)	MA40587A (es)
MD (1)	MD4800C1 (es)
ME (1)	ME02856B (es)
MX (1)	MX2017002241A (es)
MY (1)	MY192109A (es)
NI (1)	NI201700020A (es)
NO (1)	NO2721710T3 (es)
NZ (1)	NZ729005A (es)
PE (1)	PE20171177A1 (es)
PH (1)	PH12017500276A1 (es)
PL (1)	PL3183247T3 (es)
PT (1)	PT3183247T (es)
RS (1)	RS56807B1 (es)
SG (1)	SG11201700957WA (es)
SI (1)	SI3183247T1 (es)
SV (1)	SV2017005384A (es)
TN (1)	TN2017000044A1 (es)
TW (1)	TWI583681B (es)
UA (1)	UA117976C2 (es)
UY (1)	UY36275A (es)
WO (1)	WO2016027195A1 (es)
ZA (1)	ZA201701005B (es)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8940764B2 (en)	2005-05-26	2015-01-27	Aldexa Therapeutics, Inc.	Compositions and methods of treating retinal disease
CN111135171B (zh)	2013-01-23	2023-09-08	奥尔德拉医疗公司	与毒性醛相关的疾病和治疗
US10138251B2 (en)	2014-04-11	2018-11-27	Boehringer Ingelheim International Gmbh	Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors
US10576064B2 (en)	2014-07-03	2020-03-03	Boehringer Ingelheim International Gmbh	Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors
NO2721710T3 (es)	2014-08-21	2018-03-31
NZ728685A (en)	2014-08-21	2024-01-26	Boehringer Ingelheim Int	New spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors
WO2017035077A1 (en)	2015-08-21	2017-03-02	Aldeyra Therapeutics, Inc.	Deuterated compounds and uses thereof
WO2017044434A1 (en)	2015-09-11	2017-03-16	Sunshine Lake Pharma Co., Ltd.	Substituted heteroaryl compounds and methods of use
LT3359542T (lt)	2015-10-09	2021-05-25	Boehringer Ingelheim International Gmbh	Spiro[3h-indolo-3,2 -pirolidin]-2(1h)-ono junginiai ir dariniai, kaip mdm2-p53 inhibitoriai
US10028960B2 (en) *	2016-04-28	2018-07-24	Theravance Biopharma R&D Ip, Llc	Pyrimidine compounds as JAK kinase inhibitors
CA3022665A1 (en)	2016-05-09	2017-11-16	Aldeyra Therapeutics, Inc.	Combination treatment of ocular inflammatory disorders and diseases
TW201822764A (zh)	2016-09-14	2018-07-01	美商基利科學股份有限公司	Syk抑制劑
EP3512519A1 (en)	2016-09-14	2019-07-24	Gilead Sciences, Inc.	Syk inhibitors
EP3526222B1 (en) *	2016-10-14	2022-08-17	Nimbus Lakshmi, Inc.	Tyk2 inhibitors and uses thereof
CA3054811A1 (en)	2017-03-16	2018-09-20	Aldeyra Therapeutics, Inc.	Polymorphic compounds and uses thereof
WO2018195471A1 (en)	2017-04-21	2018-10-25	Gilead Sciences, Inc.	Syk inhibitors in combination with hypomethylating agents
CN108864057B (zh) *	2017-05-16	2020-03-31	山东大学	含有4-氨基吡唑结构的jak与hdac双靶点抑制剂及其制备方法和应用
CN109422753B (zh) *	2017-09-03	2021-12-31	上海美志医药科技有限公司	一类具有抑制并降解酪氨酸蛋白激酶jak1或jak2活性的化合物
CN111356451A (zh)	2017-10-10	2020-06-30	奥尔德拉医疗公司	炎性病症的治疗
JP7218364B2 (ja) *	2017-10-27	2023-02-06	セラヴァンスバイオファーマアール＆ディーアイピー，エルエルシー	Ｊａｋキナーゼ阻害剤としてのピリミジン化合物
EP3710006A4 (en)	2017-11-19	2021-09-01	Sunshine Lake Pharma Co., Ltd.	SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR METHODS OF USE
CN111989327A (zh)	2018-02-05	2020-11-24	奥克梅斯公司	用于治疗疼痛的化合物
CA3106470A1 (en)	2018-07-17	2020-01-23	Nippon Chemiphar Co., Ltd.	T-type calcium channel blocker
CN112714762A (zh)	2018-08-06	2021-04-27	奥尔德拉医疗公司	多晶型化合物及其用途
TW202035375A (zh) *	2018-09-25	2020-10-01	美商卡都瑞恩醫藥有限責任公司	胺基嘧啶化合物
WO2020068846A1 (en) *	2018-09-25	2020-04-02	Heterocyclic Compound	Heterocyclic compound
GB201816369D0 (en)	2018-10-08	2018-11-28	Sareum Ltd	Pharmaceutical compounds
CN109364248B (zh) *	2018-10-16	2021-05-18	哈尔滨医科大学	ENaC及其抑制剂在预防、缓解和/或治疗动脉粥样硬化中的应用
TW202033198A (zh) *	2018-10-17	2020-09-16	美商美國禮來大藥廠	以巴瑞克替尼(baricitinib)治療原發性膽汁性膽管炎及原發性硬化性膽管炎
US20220144846A1 (en) *	2019-02-15	2022-05-12	Pfizer Inc.	Crystalline pyrimidinyl-3,8-diazabicyclo[3.2.1]octanylmethanone compound and use thereof
CN111658628B (zh) *	2019-03-08	2022-03-01	中国科学院动物研究所	Gli2抑制剂的用途以及抑制gli2的化合物的筛选方法
WO2020182159A1 (zh)	2019-03-14	2020-09-17	上海华汇拓医药科技有限公司	Jak激酶抑制剂及其制备方法和在医药领域的应用
AU2020242287A1 (en)	2019-03-21	2021-09-02	INSERM (Institut National de la Santé et de la Recherche Médicale)	A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2020203609A1 (ja)	2019-03-29	2020-10-08	日本ケミファ株式会社	掻痒を治療するためのｔ型カルシウムチャネル阻害剤の使用
AR118768A1 (es)	2019-04-24	2021-10-27	Theravance Biopharma R&D Ip Llc	Derivados de pirimidina como inhibidores de las cinasas jak
US11439641B2 (en)	2019-04-24	2022-09-13	Theravance Biopharma R&D Ip, Llc	Pyrimidine JAK inhibitors for the treatment of skin diseases
IL287665A (en)	2019-04-30	2022-07-01	Celgene Corp	Combined treatments including apremilaste and tyk2 inhibitors
KR20220046593A (ko) *	2019-08-09	2022-04-14	더 내셔널 인스티튜츠 오브 파마슈티컬 알앤디 컴퍼니 리미티드	가교된 헤테로사이클일-치환된 피리미딘 화합물, 이의 제조 방법, 및 이의 약학 용도
AU2020347561A1 (en) *	2019-09-11	2022-04-14	Pfizer Inc.	Treatment of hidradenitis with JAK inhibitors
CN110862376A (zh) *	2019-10-24	2020-03-06	嘉兴特科罗生物科技有限公司	一种小分子化合物
US20220401436A1 (en)	2019-11-08	2022-12-22	INSERM (Institute National de la Santé et de la Recherche Médicale)	Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en)	2020-01-22	2021-07-29	Onxeo	Novel dbait molecule and its use
CN113372364A (zh) *	2020-03-10	2021-09-10	明慧医药（上海）有限公司	一类jak激酶抑制剂及其制备和应用
MX2022011188A (es) *	2020-03-17	2022-11-08	Jiangsu Hengrui Pharmaceuticals Co Ltd	Derivado biciclico fusionado, metodo de preparacion y uso farmaceutico del mismo.
CA3177852A1 (en)	2020-04-04	2021-10-07	Pfizer Inc.	Methods of treating coronavirus disease 2019
GB202005114D0 (en)	2020-04-07	2020-05-20	Sareum Ltd	Crystalline Forms of a Pharmaceutical Compound
CN111423420A (zh) *	2020-04-30	2020-07-17	广州博济医药生物技术股份有限公司	作为己酮糖激酶抑制剂的并环化合物
CN113698403B (zh) *	2020-05-21	2022-06-28	南京亘泰医药技术有限公司	(1r,4r,7r)-7-氨基-2-氮杂双环[2,2,1]庚烷衍生物及制备方法
US20240018155A1 (en) *	2020-06-09	2024-01-18	Crystal Pharmatech Co., Ltd.	New crystal form of p-toluenesulfonate salt of diazabicyclic compound and preparation method therefor
TWI785660B (zh)	2020-07-02	2022-12-01	美商輝瑞大藥廠	嘧啶基-3,8-二氮雜雙環[3.2.1]辛烷基甲酮衍生物及其鹽之製備
TWI782599B (zh) *	2020-07-02	2022-11-01	美商輝瑞股份有限公司	胺基嘧啶基衍生物
AU2021308340A1 (en)	2020-07-17	2023-02-23	Pfizer Inc.	Stable pharmaceutical topical formulation containing immunosuppressant for treating dermatological conditions
CN116438200A (zh)	2020-09-10	2023-07-14	普雷西里克斯公司	针对fap的抗体片段
KR20230131240A (ko) *	2021-01-14	2023-09-12	더 내셔널 인스티튜츠 오브 파마슈티컬 알앤디 컴퍼니 리미티드	가교된 헤테로사이클일-치환된 피리미딘 화합물, 이의제조 방법, 및 이의 의학적 용도
CN114835717A (zh) *	2021-02-01	2022-08-02	杭州领业医药科技有限公司	Brepocitinib甲苯磺酸盐的晶型及其制备方法和用途
WO2022198196A1 (en)	2021-03-15	2022-09-22	Maze Therapeutics, Inc.	Inhibitors of glycogen synthase 1 (gys1) and methods of use thereof
CN113999239B (zh) *	2021-07-14	2022-11-11	上海凌富药物研究有限公司	一种二氮杂桥化合物的合成方法
CN113698409B (zh) *	2021-08-10	2022-07-19	上海凌凯医药科技有限公司	一种多用途的二氮杂双环类化合物、制备方法及在合成药物中的应用
CN113461687B (zh) *	2021-08-10	2022-04-19	四川大学华西医院	2,8-氮杂-[4,5]十螺环酮衍生物及其制备方法和用途
CA3231865A1 (en) *	2021-09-17	2023-03-23	Tingting SHANG	Fused bicyclic derivative, pharmaceutically acceptable salt, crystal form thereof and preparation method therefor
WO2023076161A1 (en)	2021-10-25	2023-05-04	Kymera Therapeutics, Inc.	Tyk2 degraders and uses thereof
CN114181097A (zh) *	2021-12-10	2022-03-15	广东嘉博制药有限公司	一种盐酸甲氧明的合成方法
WO2023178001A1 (en) *	2022-03-17	2023-09-21	Pfizer Inc.	Methods, dosage regimens, and compositions for treating hidradenitis
WO2023203135A1 (en)	2022-04-22	2023-10-26	Precirix N.V.	Improved radiolabelled antibody
WO2023213801A1 (en)	2022-05-02	2023-11-09	Precirix N.V.	Pre-targeting
CN116396298A (zh) *	2023-06-06	2023-07-07	四川维亚本苑生物科技有限公司	CDK Ligand-1的中间体XII及CDK Ligand-1的制备方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4131139A1 (de)	1991-09-19	1993-03-25	Bayer Ag	Verfahren zur herstellung von 1-fluor-cyclopropan-1-carbonsaeure
CN1930112B (zh)	2004-03-31	2010-06-23	第一制药株式会社	1,2-顺式-2-氟环丙烷-1-甲酸酯类的制造方法
WO2006109846A1 (ja)	2005-04-06	2006-10-19	Takeda Pharmaceutical Company Limited	トリアゾール誘導体およびその用途
EA200800664A1 (ru)	2005-10-13	2009-02-27	Глаксо Груп Лимитед	Производные пирролопиримидина в качестве ингибиторов syk
NL2000323C2 (nl)	2005-12-20	2007-11-20	Pfizer Ltd	Pyrimidine-derivaten.
BRPI0706537A2 (pt)	2006-01-17	2011-03-29	Vertex Pharma	azaindóis úteis como inibidores de janus cinases
EP2057147A1 (en) *	2006-09-14	2009-05-13	Astra Zeneca AB	Pyrimidine derivatives
WO2008032033A1 (en) *	2006-09-14	2008-03-20	Astrazeneca Ab	4-benzimidazolyl-2-morpholino-6-piperazinylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
TW200904437A (en) *	2007-02-14	2009-02-01	Janssen Pharmaceutica Nv	2-aminopyrimidine modulators of the histamine H4 receptor
PE20090996A1 (es) *	2007-04-02	2009-07-15	Palau Pharma Sa	Derivados de pirrolopirimidina como inhibidores de cinasa jak3
US8188083B2 (en)	2007-06-28	2012-05-29	Abbott Laboratories	Triazolopyridazines
US8076491B2 (en)	2007-08-21	2011-12-13	Senomyx, Inc.	Compounds that inhibit (block) bitter taste in composition and use thereof
BRPI0915761A2 (pt)	2008-07-16	2015-11-03	Hoffmann La Roche	composto de heterociclila para tratamento de doença cardiovascular
WO2010075273A1 (en)	2008-12-23	2010-07-01	Schering Corporation	Bicyclic heterocycle derivatives and methods of use thereof
CA2767079A1 (en) *	2009-07-08	2011-01-13	Leo Pharma A/S	Heterocyclic compounds as jak receptor and protein tyrosine kinase inhibitors
WO2012022681A2 (en)	2010-08-20	2012-02-23	Cellzome Limited	Heterocyclyl pyrazolopyrimidine analogues as selective jak inhibitors
WO2013041042A1 (en)	2011-09-22	2013-03-28	Merck Sharp & Dohme Corp.	Pyrazole carboxamides as janus kinase inhibitors
EP2791347A2 (en)	2011-12-16	2014-10-22	Invista Technologies S.à.r.l.	METHODS OF PRODUCING 6-CARBON CHEMICALS VIA CoA-DEPENDENT CARBON CHAIN ELONGATION ASSOCIATED WITH CARBON STORAGE
NO2721710T3 (es)	2014-08-21	2018-03-31
NZ728685A (en)	2014-08-21	2024-01-26	Boehringer Ingelheim Int	New spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors

2012
- 2012-06-19 NO NO12803361A patent/NO2721710T3/no unknown
2015
- 2015-08-07 DK DK15766627.2T patent/DK3183247T3/en active
- 2015-08-07 CU CU2017000015A patent/CU24435B1/es unknown
- 2015-08-07 ME MEP-2017-284A patent/ME02856B/me unknown
- 2015-08-07 RS RS20180079A patent/RS56807B1/sr unknown
- 2015-08-07 WO PCT/IB2015/056021 patent/WO2016027195A1/en active Application Filing
- 2015-08-07 BR BR112017003054-3A patent/BR112017003054B1/pt active IP Right Grant
- 2015-08-07 EA EA201700077A patent/EA032609B1/ru unknown
- 2015-08-07 MD MDA20170016A patent/MD4800C1/ro active IP Right Grant
- 2015-08-07 SG SG11201700957WA patent/SG11201700957WA/en unknown
- 2015-08-07 JP JP2017509666A patent/JP6218260B2/ja active Active
- 2015-08-07 EP EP15766627.2A patent/EP3183247B9/en active Active
- 2015-08-07 TN TN2017000044A patent/TN2017000044A1/en unknown
- 2015-08-07 MA MA040587A patent/MA40587A/fr unknown
- 2015-08-07 ES ES15766627.2T patent/ES2655971T3/es active Active
- 2015-08-07 GE GEAP201514430A patent/GEP20197003B/en unknown
- 2015-08-07 UA UAA201701672A patent/UA117976C2/uk unknown
- 2015-08-07 KR KR1020177007276A patent/KR101877189B1/ko active IP Right Grant
- 2015-08-07 CR CR20170066A patent/CR20170066A/es unknown
- 2015-08-07 HU HUE15766627A patent/HUE035553T2/hu unknown
- 2015-08-07 AP AP2017009748A patent/AP2017009748A0/en unknown
- 2015-08-07 AU AU2015304883A patent/AU2015304883B2/en active Active
- 2015-08-07 MY MYPI2017700538A patent/MY192109A/en unknown
- 2015-08-07 CN CN201580057140.5A patent/CN107074867B/zh active Active
- 2015-08-07 SI SI201530156T patent/SI3183247T1/en unknown
- 2015-08-07 LT LTEP15766627.2T patent/LT3183247T/lt unknown
- 2015-08-07 MX MX2017002241A patent/MX2017002241A/es active IP Right Grant
- 2015-08-07 NZ NZ729005A patent/NZ729005A/en unknown
- 2015-08-07 PE PE2017000248A patent/PE20171177A1/es unknown
- 2015-08-07 PL PL15766627T patent/PL3183247T3/pl unknown
- 2015-08-07 PT PT157666272T patent/PT3183247T/pt unknown
- 2015-08-18 CA CA2900855A patent/CA2900855C/en active Active
- 2015-08-19 US US14/829,753 patent/US9663526B2/en active Active
- 2015-08-19 UY UY0001036275A patent/UY36275A/es active IP Right Grant
- 2015-08-20 TW TW104127204A patent/TWI583681B/zh active
- 2015-08-20 AR ARP150102681A patent/AR101599A1/es unknown
2017
- 2017-02-09 ZA ZA2017/01005A patent/ZA201701005B/en unknown
- 2017-02-14 PH PH12017500276A patent/PH12017500276A1/en unknown
- 2017-02-16 EC ECIEPI201710156A patent/ECSP17010156A/es unknown
- 2017-02-16 SV SV2017005384A patent/SV2017005384A/es unknown
- 2017-02-17 CO CONC2017/0001603A patent/CO2017001603A2/es unknown
- 2017-02-20 CL CL2017000406A patent/CL2017000406A1/es unknown
- 2017-02-20 NI NI201700020A patent/NI201700020A/es unknown
- 2017-02-21 IL IL250709A patent/IL250709B/en active IP Right Grant
- 2017-02-21 GT GT201700035A patent/GT201700035A/es unknown
- 2017-02-21 DO DO2017000048A patent/DOP2017000048A/es unknown
- 2017-05-03 US US15/585,626 patent/US10463675B2/en active Active
- 2017-12-11 HR HRP20171913TT patent/HRP20171913T1/hr unknown
2018
- 2018-01-10 CY CY20181100036T patent/CY1119771T1/el unknown
2019
- 2019-09-24 US US16/580,667 patent/US10980815B2/en active Active
2020
- 2020-07-02 US US16/920,027 patent/US11197867B2/en active Active
2021
- 2021-08-06 US US17/396,094 patent/US20210377495A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CN107074867A (zh)	2017-08-18
HRP20171913T1 (hr)	2018-02-09
EP3183247B1 (en)	2017-11-29
NZ729005A (en)	2020-06-26
MD4800B1 (ro)	2022-03-31
US20200038409A1 (en)	2020-02-06
MY192109A (en)	2022-07-27
ECSP17010156A (es)	2017-11-30
WO2016027195A1 (en)	2016-02-25
CA2900855A1 (en)	2016-02-21
IL250709B (en)	2019-05-30
EA032609B1 (ru)	2019-06-28
ZA201701005B (en)	2019-07-31
ME02856B (me)	2018-04-20
PL3183247T3 (pl)	2018-03-30
US20160052930A1 (en)	2016-02-25
CY1119771T1 (el)	2018-06-27
CL2017000406A1 (es)	2017-10-06
MD20170016A2 (ro)	2017-08-31
UY36275A (es)	2016-04-01
AU2015304883B2 (en)	2018-05-10
NI201700020A (es)	2017-05-02
DK3183247T3 (en)	2018-01-15
PE20171177A1 (es)	2017-08-22
MA40587A (fr)	2017-06-28
JP2017524022A (ja)	2017-08-24
PT3183247T (pt)	2018-01-18
MX2017002241A (es)	2017-05-03
US10980815B2 (en)	2021-04-20
CR20170066A (es)	2017-07-17
SG11201700957WA (en)	2017-03-30
TW201609706A (zh)	2016-03-16
BR112017003054B1 (pt)	2023-04-11
EP3183247A1 (en)	2017-06-28
LT3183247T (lt)	2018-01-25
US9663526B2 (en)	2017-05-30
US10463675B2 (en)	2019-11-05
CA2900855C (en)	2022-03-15
US20170239264A1 (en)	2017-08-24
US20200330477A1 (en)	2020-10-22
DOP2017000048A (es)	2017-06-30
US20210377495A1 (en)	2021-12-02
EA201700077A1 (ru)	2017-07-31
KR101877189B1 (ko)	2018-07-10
KR20170036109A (ko)	2017-03-31
ES2655971T3 (es)	2018-02-22
SI3183247T1 (en)	2018-02-28
BR112017003054A2 (pt)	2017-11-21
TWI583681B (zh)	2017-05-21
PH12017500276A1 (en)	2017-07-03
SV2017005384A (es)	2017-07-10
AP2017009748A0 (en)	2017-02-28
IL250709A0 (en)	2017-04-30
ES2655971T9 (es)	2018-09-14
HUE035553T2 (hu)	2018-05-02
CU20170015A7 (es)	2017-06-05
CN107074867B (zh)	2019-10-22
AU2015304883A1 (en)	2017-03-02
TN2017000044A1 (en)	2018-07-04
GEP20197003B (en)	2019-07-25
EP3183247B9 (en)	2018-07-25
US11197867B2 (en)	2021-12-14
MD4800C1 (ro)	2022-10-31
GT201700035A (es)	2019-10-10
CO2017001603A2 (es)	2017-05-10
RS56807B1 (sr)	2018-04-30
UA117976C2 (uk)	2018-10-25
JP6218260B2 (ja)	2017-10-25
AR101599A1 (es)	2016-12-28
CU24435B1 (es)	2019-09-04

Publication	Publication Date	Title
BR112014020027A2 (es)	2017-06-20
BR112014017635A2 (es)	2017-06-20
BR112014018164A2 (es)	2017-06-20
NO2721710T3 (es)	2018-03-31
BR112014017592A2 (es)	2017-06-20
BR112014019495A2 (es)	2017-06-20
BR112014030852A2 (es)	2017-08-15
BR112014017659A2 (es)	2017-06-20
BR112014019838A2 (es)	2017-06-20
BR112014017638A2 (es)	2017-06-20
AR092201A1 (es)	2015-04-08
BR112014017607A2 (es)	2017-06-20
BR112014020054A2 (es)	2017-06-20
BR112013027865A2 (es)	2017-01-03
BR112014019383A2 (es)	2017-06-20
BR112014017634A2 (es)	2017-06-20
BR112014017673A2 (es)	2017-06-20
BR112014017588A2 (es)	2017-06-20
BR112014013184A8 (es)	2017-06-27
BR112014017630A2 (es)	2017-06-20
BR112014017652A2 (es)	2017-06-20
BR112014017641A2 (es)	2017-06-20
BR112014017631A2 (es)	2017-06-20
BR112014017636A2 (es)	2017-06-20
BR112014017667A2 (es)	2017-06-20